Lipella Pharmaceuticals I... (LIPO)
NASDAQ: LIPO
· Real-Time Price · USD
2.36
0.00 (0.00%)
At close: Jun 18, 2025, 3:59 PM
0.00% (1D)
| Bid | n/a |
| Market Cap | 10.54M |
| Revenue (ttm) | 129.78M |
| Net Income (ttm) | -1.31B |
| EPS (ttm) | -4.12 |
| PE Ratio (ttm) | -0.57 |
| Forward PE | -0.14 |
| Analyst | Buy |
| Ask | n/a |
| Volume | 144,073 |
| Avg. Volume (20D) | 80,522 |
| Open | 2.71 |
| Previous Close | 2.36 |
| Day's Range | 2.36 - 2.71 |
| 52-Week Range | 1.97 - 12.00 |
| Beta | 0.46 |
About LIPO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LIPO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LIPO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+41.64%
Lipella Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
4 months ago
+80.23%
Lipella Pharmaceuticals shares are trading higher after the company received FDA approval for an expanded access program for LP-310 in oral lichen planus.
1 month ago · prismmediawire.com
Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”Listen: PITTSBURGH, April 23, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
2 months ago · prismmediawire.com
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse PodcastEpisode titled “From Medicine to Biotech Innovation” now available PITTSBURGH, March 31, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”)...